|
Indications and Dosage
Endotracheal
Neonatal respiratory distress syndrome Child: Premature neonates <29 weeks gestational age and newborns ≤72 hours of age: 105 mg phospholipids/kg (3 mL/kg) given as soon as possible, preferably within 30 minutes of birth (as prophylaxis), or as soon as diagnosis is confirmed (as treatment). May repeat dose every 12 hours for a total of up to 3 doses if with continued distress.
|
|
Special Precautions
Infant at risk of intraventricular haemorrhage and periventricular leukomalacia. Not indicated as a substitute for neonatal intensive care. Children.
|
|
Adverse Reactions
Significant: Cyanosis, airway obstruction, bradycardia, reflux into the endotracheal tube, reintubation, hypoventilation.
|
|
MonitoringParameters
Monitor heart rate and transcutaneous oxygen saturation during administration. Perform frequent arterial blood gas sampling after initial dose.
|
|
Action
Description: Calfactant, an endogenous lung surfactant, from calf lung extract of phospholipid, neutral lipids and hydrophobic surfactant-associated proteins B and C. It restores surface activity to the lungs by modifying the alveolar surface tension thus, stabilising the alveoli. It adsorbs rapidly to the surface of the air, liquid interface and modifies surface tension similarly to natural lung surfactant.
Onset: 24-48 hours. |
|
Storage
Store upright, between 2-8°C. Do not freeze. Do not shake. Protect from light.
|
|
MIMS Class
|
|
References
Anon. Calfactant. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 09/05/2019. Buckingham R (ed). Pulmonary Surfactants. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 09/05/2019. Infasurf (Ony Biotech Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 09/05/2019.
|
Manage Account
Change Password
Sign Out
